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Abstract
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transduction activity. Most
castration-resistant prostate tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes,
despite the near absence of circulating androgen in these patients. The AR is regulated not only by its cognate steroid
hormone, but also by interactions with a constellation of co-regulatory and signaling molecules. Thus, the elevated
signaling activity that occurs during progression to castration resistance can affect prostate cancer cell growth either
through the AR or independent of the AR. In order to identify signaling pathways that regulate prostate cancer cell growth,
we screened a panel of shRNAs targeting 673 human kinases against LNCaP prostate cancer cells grown in the presence and
absence of hormone. The screen identified multiple shRNA clones against known and novel gene targets that regulate
prostate cancer cell growth. Based on the magnitude of effect on growth, we selected six kinases for further study:
MAP3K11, DGKD, ICK, CIT, GALK2, and PSKH1. Knockdown of these kinases decreased cell growth in both androgen-
dependent and castration-resistant prostate cancer cells. However, these kinases had different effects on basal or androgen-
induced transcriptional activity of AR target genes. MAP3K11 knockdown most consistently altered transcription of AR
target genes, suggesting that MAP3K11 affected its growth inhibitory effect by modulating the AR transcriptional program.
Consistent with MAP3K11 acting on the AR, knockdown of MAP3K11 inhibited AR Ser 650 phosphorylation, further
supporting stress kinase regulation of AR phosphorylation. This study demonstrates the applicability of lentiviral-based
shRNA for conducting phenotypic screens and identifies MAP3K11, DGKD, ICK, CIT, GALK2, and PSKH1 as regulators of
prostate cancer cell growth. The thorough evaluation of these kinase targets will pave the way for developing more
effective treatments for castration-resistant prostate cancer.
Citation: Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, et al. (2012) Identification of Kinases Regulating Prostate Cancer Cell Growth Using an RNAi
Phenotypic Screen. PLoS ONE 7(6): e38950. doi:10.1371/journal.pone.0038950
Editor: Jindan Yu, Northwestern University, United States of America
Received January 11, 2012; Accepted May 15, 2012; Published June 27, 2012
Copyright:  2012 Whitworth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institute of Health Grant R01 CA124706 to DG and the Paul Mellon Urologic Cancer Institute at the University of
Virginia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Andrea Spencer, Ronald Hernan, and Heather Holemon were
employed at Sigma-Aldrich Biotechnology during the RNAi screen. Sigma-Aldrich sells the MISSION library that was used in this study. This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: dgioeli@virginia.edu
Introduction
The androgen receptor (AR) is a critical regulator of prostate
cancer progression and it is increasingly clear that the AR is
regulated not only by its cognate steroid hormone, but also by
interactions with a constellation of co-regulatory and signaling
molecules [1–3]. For patients presenting with disseminated
prostate cancer, the tumor is typically dependent on androgen
for growth and therefore, initially responsive to surgical and/or
pharmacological depletion of circulating androgens [4]. However,
therapeutic success is temporary. The cancer almost invariably
recurs and progresses to a metastatic and lethal disease. The
extensive cross talk between signaling pathways, such as androgen
and peptide signaling pathways, multiple genetic mutations, and
the genetic plasticity of cancer, all contribute to the inherent and
acquired resistance to androgen ablation [5].
Previous studies have demonstrated that polypeptide growth
factor signal transduction pathways can stimulate AR activation,
suggesting that the increase in growth factor and receptor
expression could be causal in prostate cancer progression to
castration resistance. Growth factor stimulation has been reported
to render AR-responsive promoters hypersensitive to androgen
[6–14], and forced over expression of HER2/neu in androgen-
dependent prostate cancer cells has been shown to drive
castration-resistant growth [15,16]. Moreover, inhibition of
EGFR/HER2 signaling can inhibit prostate cancer cell growth
in vitro and in vivo [17,18] as well as AR transcriptional activity,
protein stability, DNA binding, and Ser 81 phosphorylation [19].
The ability of signaling cascades to influence AR function may
play a significant role in the development and progression of
prostate cancer where the increase in signal transduction activity
has been associated with the acquisition of castration-resistant
disease. This suggests that therapeutic strategies targeting kinase
cascades can overcome the compensatory signaling mechanisms
that limit the effectiveness of androgen ablation.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38950In order to identify the signaling pathways that regulate prostate
cancer cell growth, we screened a panel of shRNAs that target the
human kinome against LNCaP prostate cancer cells grown in the
presence and absence of androgen. We searched for kinases that
had general growth effects and kinases that compensated for
androgen ablation. The screen identified multiple shRNA clones
against gene targets that regulate both androgen sensitivity and
cell growth. We report here the results of our screen and the
detailed evaluation of a subset of kinases identified as regulators of
prostate cancer cell growth.
Results
Prior to screening a panel of shRNAs that target the human
kinome against LNCaP prostate cancer cells, we performed careful
optimization of parameters, including cell growth conditions,
multiplicity of infection, puromycin selection, androgen treatment,
and cell viability measurements (data not shown). We identified
shRNA clones that decreased and increased LNCaP cell growth in
both the presence and absence of androgen (Figure 1). The
screen used the MISSIONH library with three to five shRNAs for
each of 673 kinase targets; three independent biological replicates
were performed on separate days. Following knockdown, altera-
tions in LNCaP cell metabolism were determined using Alamar-
Blue as a surrogate for cell proliferation. Multiple shRNA clones
against gene targets affecting cell growth were identified.
There was no difference in growth when comparing pLKO
empty vector to a non-target control (NTC) (n=82, data not
shown). Androgen-treated cells grew 3.2 fold greater than vehicle-
treated cells (n=82). AR knockdown using shRNA was used as
a positive control in the screen, inhibiting growth by more than
60% in cells grown in the presence of androgen (n=41, data not
shown) but having minimal effect on LNCaP cells grown in the
absence of androgen (n=41, data not shown). In the presence of
androgen, we scored shRNAs that inhibited growth by at least
75%, which represents less than the top 1% of shRNAs inhibiting
growth, as shRNAs targeting kinases that positively regulate
LNCaP cell growth. In the absence of androgen, we scored
shRNAs that inhibited growth by 50% or more, which represents
less than the top 2% of shRNAs inhibiting growth, as shRNAs
targeting kinases that positively regulate LNCaP cell growth.
Using these criteria, shRNA knockdown of 46 kinases inhibited
cell growth. Interestingly, very few shRNAs showed an effect that
was dependent on the presence or absence of androgen. Most
shRNAs inhibited growth under both conditions, although the
magnitude of inhibition varied, indicating that this screen did not
reveal kinases that specifically regulate androgen-induced LNCaP
cell growth. Ribosomal protein S6 kinase (RPS6KA3), which has
been implicated in regulating AR activity and prostate cancer cell
growth [20–24], was identified in this screen, supporting an RNAi
screening approach to identify kinases regulating prostate cancer
cell growth. We also observed 34 kinases representing the top 1%,
whose knockdown increased LNCaP cell growth (Figure 1).
We selected six inhibitory kinases for further study based on the
magnitude of effect by shRNA knockdown: mitogen-activated
protein kinase kinase kinase 11 (MAP3K11), diacylglycerol kinase
delta (DGKD), intestinal cell kinase (ICK), citron rho interacting
kinase (CIT), galactokinase2 (GALK2), and protein serine kinase
H1 (PSKH1). One prediction posits that if the kinases that
decrease growth when knocked down are causal in prostate cancer
progression, then the activity of these kinases should increase
Figure 1. shRNA kinome-wide screen. LNCaP cells were transduced in triplicate with three to five shRNAs targeted against 673 human kinases.
Cell growth was measured by alamarBlue on day 7. Plotted is the cell growth relative to pLKO empty vector control in response to each shRNA in the
presence and absence of hormone (0.05 nM R1881). The red and green lines demarcate cut off points based on controls including pLKO, NTC, media
alone, and AR shRNA. The red line indicates growth inhibition and the green line growth.
doi:10.1371/journal.pone.0038950.g001
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the activation state of the kinases, we examined kinase message
levels in the Oncomine database. We found that in at least two
independent studies the mRNA levels for the six kinases increased
either when primary prostate cancer is compared to normal
prostate or when metastatic prostate cancer is compared to
primary disease or normal prostate (Figure S1).
We validated the growth effect and knockdown of our six
selected kinases using the CyQuant Assay, which measures DNA
content as a surrogate for cell number, and used this technique to
also extend our analysis to the castration-resistant cell line, C4-2B.
The cells were transduced with lentiviral particles expressing two
shRNAs specific for each kinase of interest or pLKO empty vector
control in the presence (0.05 nM R1881) or absence of androgen.
As observed in Figure 2, growth was decreased in both cell lines in
response to each shRNA. In general, kinase knockdown inhibited
growth in the presence and absence of androgen. Furthermore,
kinase knockdown affected growth equivalently in both the
androgen-dependent LNCaP and castration-resistant C4-2B cell
line.
qPCR was used to determine kinase knockdown by shRNA in
LNCaP and C4-2B cells (Figure 3). Hormone was added at
various concentrations (vehicle, 0.05, 0.5, and 1 nM R1881) and
RNA was isolated at 2 and 24 hours following hormone
treatment. These hormone treatments were the same as those
used to assess the effect of kinase knockdown on AR
transcriptional activity, which is described below and presented
in Table 1. Each kinase was knocked down in both cell lines with
two different shRNAs and compared to the pLKO empty vector
control. We did not observe an effect of hormone dose on the
efficiency of kinase knockdown (Figure S2); thus, the data
shown in Figure 3 are the qPCR values averaged across
biological replicates and hormone concentrations for each
shRNA or the pLKO control at 24 hours following hormone
stimulation. The shRNA viruses elicit greater than 50%
knockdown of the target kinase mRNA as compared to pLKO,
with most knockdowns greater than 70% at both time points and
in both cell lines. Essentially identical observations were made for
kinase knockdown following 2 hours of hormone stimulation
(data not shown).
There was some differential knockdown of kinase mRNA by
shRNA, which may account for the differential knockdown of
growth. For example, in LNCaP cells, CIT shRNA-2 elicited
a greater growth inhibition than CIT shRNA-1, which parallels
the effect on kinase mRNA knockdown, where CIT shRNA-2
reduced CIT mRNA levels more than CIT shRNA-1. However,
the parallels between growth inhibition and mRNA knockdown
are not evident for all kinases targeted.
In order to determine if the inhibition of growth induced by
kinase knockdown was specific to prostate cancer cells, we
measured the growth of LHS and MCF10A cells in response to
shRNA targeting the seven kinases (Figure 4). LHS cells are non-
tumorigenic immortalized human prostate epithelial cells gener-
ated by ectopic expression of SV40 large, small T antigen, and
human telomerase [25]. MCF10A is a non-tumorigenic, sponta-
neously immortalized breast epithelial cell line [26]. LNCaP cells
served as a control, with parallel experiments demonstrating
inhibition of LNCaP cell growth and kinase expression (data not
shown). In general, shRNA directed against the kinases had
minimal effect on LHS and MCF10A cell growth, suggesting
selectivity towards prostate cancer cells (Figure 4). The knock-
down of kinase message in LHS and MCF10A cells was variable
(data not shown). In LHS cells, MAP3K11 was effectively knocked
down (75 to 90% inhibition) and PSKH1 (50% inhibition);
however the knockdown was inefficient for the other kinases. In
MCF10A cells, CIT was inhibited (80%) and PSKH1, DGKD,
and GALK2 were each inhibited by approximately 50%. The
inability to inhibit kinase expression to a similar extent as in
LNCaP, C4-2B, (Figure 3) and CWR22Rv1 cells (data not
shown), complicates interpreting the importance of these kinases in
normal cell growth and survival. However, all six kinases were
knocked down in at least one of the normal cell lines tested. Thus,
these results are consistent with there being selectivity for targeting
these kinases in cancer cells over normal cells.
Since the AR is a major regulator of prostate cancer cell growth,
we wanted to determine if any of the six selected kinases might
affect growth through regulating the AR transcriptome. To
examine the effect of kinase knockdown on AR target gene
transcription, qPCR was used to measure transcript levels of two
AR target genes, TMPRSS2 and SGK, in LNCaP and C4-2B cells
with two independent shRNAs used to inhibit kinase expression
(Table 1). We examined transcription of these genes at 2 and 24
hours to evaluate the effect of kinase knockdown on the
immediate-early response and steady-state levels of AR transcrip-
tional activity. Statistical analysis indicates that there was no effect
of hormone dose on the ability of kinase knockdown to affect AR
transcription; kinase knockdown altered transcription equivalently,
or had no effect, at each androgen dose. Maintenance of androgen
induction in pLKO was observed in all analyzed experiments.
Reported in Table 1 are the statistically significant changes in AR
transcription of TMPRSS2 and SGK in response to kinase
knockdown by two independent shRNAs at 2 and 24 hours post
three different androgen dose treatments. Both shRNAs had to
alter gene transcription significantly in the same direction for
reporting in the table.
There was no consistent decrease in AR transcriptional activity
in response to knockdown of the six kinases across both cell lines,
AR target genes examined, and the two time points tested
(Table 1). Knockdown of MAP3K11 decreased transcription of
TMPRSS2 in LNCaP cells at 24 hours and in C4-2B cells at 2
hours after the addition of androgen. However, MAP3K11
knockdown increased transcription of SGK in C4-2B cells 2
hours after the addition or hormone. Knockdown of DGKD
decreased transcription of TMPRSS2 in C4-2B cells and of SGK
in LNCaP cells at 24 hours. There was no change in TMPRSS2 or
SGK transcription in either cell line as a result of the knockdown
of ICK or PSKH1. CIT knockdown has disparate effects on AR
transcription. Interestingly, the most consistent effect on AR
transcription was from GALK2 knockdown, which caused an
increase in SGK at 24 hours after hormone addition in both cell
lines and at 2 hours in C4-2B cells. However, examining only
TMPRSS2 and SGK as representative AR target genes may
create selection bias; therefore, we expanded our analysis of AR-
regulated genes.
We analyzed 14 additional genes, including the AR-activated
genes PSA, FKBP51, ORM1, STAG, Nkx3.1, FASN, AQP3,
KLK2, and UGT2B; the AR-repressed genes DKK and FST; and
the castration-resistant prostate cancer AR-regulated genes
CDC20, CDK1, and UBE2C. Transcription in LNCaP cells
following MAP3K11 knockdown was examined at 24 hours after
androgen treatment. As expected, androgen induced or repressed
transcription of all AR target genes in pLKO control cells. The
effect of MAP3K11 knockdown on AR transcription is target
dependent. Androgen-stimulated transcription of TMPRSS2,
SGK, and ORM1 was reduced in response to MAP3K11
knockdown (Figure 5A). The inverse was true for the andro-
gen-repressed genes DKK and FST. MAP3K11 knockdown
stimulated gene expression and diminished the amount of
Novel Kinases Regulating Prostate Cancer Growth
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Nkx3.1, FASN, AQP3, KLK2, and UGT2B did not change in
response to MAP3K11 knockdown. Insofar as this subset of AR
target genes represents the AR transcriptome, these data suggest
that the inhibition of cell growth in response to MAP3K11 kinase
knockdown may be due to regulation of AR transcriptional activity
on a subset of AR-regulated genes. The AR selectively regulates
cell cycle regulated genes such as CDC20, CDK1, and UBE2C to
promote cell growth [27]. We found that MAP3K11 knockdown
led to a slight, but statistically significant reduction in transcription
of these M-phase AR-regulated genes (Figure 5C).
Previously, we demonstrated that stress kinases could regulate
AR Ser 650 phosphorylation [28]. Thus, to further explore the
mechanism of MAP3K11 regulation of prostate cancer cell growth
and AR transcription, we tested if MAP3K11 knockdown
regulated AR Ser 650 phosphorylation since MAP3K11 is an
upstream regulator of JNK activity. PMA induced AR Ser 650
phosphorylation in LNCaP and C4-2B cells more than 3 fold
Figure 2. Kinase knockdown effect on growth. The relative effect of two independent shRNAs per kinase on cell growth in LNCaP (A) and C4-2B
(B) cells. CyQuant Assay measured DNA content as a surrogate for cell number 7 days after shRNA transduction. The experiment was done in the
presence and absence of hormone (0.05 nM R1881), n=3 to 7 depending on the kinase. Cell growth was compared to untreated pLKO control and
the values were averaged across biological replicates. Error bars represent standard error of the mean. denotes statistical significance.
doi:10.1371/journal.pone.0038950.g002
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MAP3K11 protein expression, with MAP3K11 shRNA-1 de-
creasing expression to a greater extent than MAP3K11 shRNA-2.
Similar alterations in c-Jun phosphorylation were observed,
suggesting that the MAP3K11 shRNAs inhibited PMA-induced
stress kinase signaling. Under these conditions, AR Ser 650
phosphorylation was decreased in both LNCaP and C4-2B cells. A
parallel decrease in total AR was observed. Quantitation of the
relative amount of Ser 650 phosphorylation to total AR showed
a reduction in phospho-Ser 650 (Figure 6 histogram), suggesting
a stoichiometric change in AR Ser 650 phosphorylation in
response to MAPK3K11 knockdown. MAP3K11 shRNA-1 had
the greatest impact on AR Ser 650 phosphorylation, paralleling
the effect on MAP3K11 protein expression and c-Jun phosphor-
ylation. These observations are consistent with our earlier results
which suggest that stress kinase signaling regulates AR Ser 650
phosphorylation [28] and further suggest that MAP3K11 knock-
down may be eliciting growth inhibition through interruption of
the AR.
Discussion
Our study demonstrates the applicability of lentiviral-based
shRNA for conducting phenotypic screens to identify targets
involved in prostate cancer growth. The signaling pathways
regulating prostate cancer cell growth and AR activity play
a pivotal role in the transition from androgen-dependent prostate
cancer to castration-resistant disease [29]. In order to identify
Figure 3. shRNA effect on target expression. Kinase transcript levels in LNCaP (A) and C4-2B (B) cells following knockdown with two
independent shRNAs per kinase. Transcript levels were measured by qPCR on day 4 following transduction and 2 hours after R1881 hormone
treatment (vehicle, 0.05, 0.5, and 1 nM). Transcript levels were compared to untreated pLKO control and normalized to the housekeeping gene,
PSMB6. Values were averaged across hormone concentrations and biological replicates. Error bars represent standard error of the mean. denotes
statistical significance.
doi:10.1371/journal.pone.0038950.g003
Novel Kinases Regulating Prostate Cancer Growth
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38950kinases within these networks, we examined how RNAi knock-
down of kinases affects LNCaP prostate cancer cell growth. We
predicted finding both novel and known regulators of growth. The
screen identified kinases previously shown to regulate prostate
cancer cell growth and AR activity, including the ribosomal S6
kinase (RPS6KA3 or RSK) [30]. RSK is downstream of MAPK
and enhances PSA transcription. Chemical inhibition of RSK
decreased PSA expression and prostate cancer cell growth [30].
RSK appears to mediate AR transcriptional activation through its
own kinase function as well as interactions with p300, an AR co-
regulator with HAT activity. Identifying RSK in our screen
supports hypomorphic genetic screens to identify kinases regulat-
ing prostate cancer cell growth.
Multiple targets were identified in our RNAi screen, suggesting
that multiple kinase signaling pathways regulate prostate cancer
cell growth. We selected six kinases for further study, including
MAP3K11, DGKD, ICK, CIT, GALK2, and PSKH1. Knock-
down of all six kinases was found to decrease cell growth in both
androgen-dependent and castration-resistant prostate cancer cells.
To determine if the growth effect was mediated through the AR,
we initially examined transcription of two well-characterized AR
responsive genes, TMPRSS2 and SGK. We did not observe
a consistent effect across the time points and cell lines tested on AR
transcription of TMPRSS2 and SGK when the six kinases were
knocked down. However, when we expanded our analysis to 16
total AR-regulated genes in response to MAP3K11 knockdown,
we found that a subset of AR target genes was altered. This
suggests that MAP3K11 knockdown can modulate AR transcrip-
tional activity and may mediate its growth effects through the AR.
Additionally, these data add to the evidence that the AR can be
regulated in a promoter selective manner, allowing it to serve as an
integrator of multiple extracellular signals. Our lab and others
have reported this in previous studies [31,32]. Further experiments
involving additional AR target genes will be necessary to fully
evaluate the effects of knockdown of these six kinases on AR
transcription.
MAP3K11, also called Mixed Lineage Kinase (MLK3), is
a member of the serine/threonine kinase family that preferentially
activates MAPK8/JNK kinase and functions as a positive
regulator of JNK signaling [33]. Additionally, this kinase can
directly phosphorylate and activate IkappaB kinase and is involved
in the transcriptional activity of NF-kappaB mediated by Rho
family GTPases. MAP3K11 is required for serum-stimulated cell
proliferation and for mitogen and cytokine activation of p38,
ERK, and JNK1. MAP3K11 also plays a role in mitogen-
stimulated phosphorylation and activation of BRAF, without
phosphorylating BRAF directly. Thus, MAP3K11 functions as
a node in the mitogen and stress signaling pathways. We have
previously shown that activation of the MAP kinase pathway
correlates with prostate cancer progression in a variety of settings
and determined that stress kinase signaling regulates AR Ser 650
phosphorylation [28,34]. In this study, we confirmed that stress
kinase signaling regulates AR Ser 650 phosphorylation; knock-
down of MAP3K11 stoichiometrically decreased PMA-induced
AR Ser 650 phosphorylation. Modulation of Ser 650 phosphor-
ylation may be regulating AR transcriptional activity of the AR
target genes that were altered upon MAP3K11 knockdown,
including TMPRSS2, SGK, ORM1, DKK and FST. We also
found that the castration-resistant prostate cancer AR regulated
M-phase genes CDC20, CDK1, and UBE2C [27], were decreased
in response to MAP3K11 knockdown, although the decrease in
transcription of these genes may reflect the inhibition of growth
triggered by MAP3K11 knockdown and not represent altered AR
transcriptional activity. Our screen also identified other stress
kinases, including MAP3K7, MAP4K3, and MAPKAPK5 (data
not shown), which underscores the critical nature of stress kinase
signaling in regulating prostate cancer cell growth.
DGKD is an enzyme that phosphorylates diacylglycerol (DAG)
to produce phosphatidic acid (PA). DGK catalyzes the phosphor-
ylation of DAG by converting it to PA, thereby exchanging one
second messenger for another and activating protein kinase C
(PKC) [35]. There is increasing evidence suggesting that DGKD is
involved in regulating DAG and PA levels in response to various
growth factors and hormones [35]. DGKD was reported to
interact with RACK1, a protein that we had previously
demonstrated as an AR interacting protein that regulates AR
phosphorylation and transcriptional activity [36,37]. Thus,
DGKD may contribute to AR regulation through RACK1.
However, knockdown of DGKD did not have a significant effect
on AR transcriptional activity. Previous research has shown that in
the absence of DGKD, EGFR signaling is decreased because both
expression and kinase activity are inhibited [38]. This effect on
EGFR is a result of a decrease in a deubiquitinase, USP-8, and
therefore increased ubiquitination and degradation of the EGFR
[38]. Growth factor signaling is a known regulator of prostate
cancer cell growth [29]. It is therefore possible that the growth
effect that corresponds with DGKD knockdown is the result of
altered receptor tyrosine kinase signaling.
Table 1. AR transcriptional activity in response to kinase knockdown.
LNCaP C4-2B
TMPRSS2 SGK TMPRSS2 SGK
22 422 422 42 2 4
CIT 2 Qq 22 2q 2
DGKD 22 2Q 2 Q 22
GALK2 22 2q 22 qq
ICK 2 22 22 222
PSKH1 2 22 22 222
MAP3K11 2 Q 22 Q 22q
Each of the six kinases was knocked down using two independent shRNAs in LNCaP and C42B cells. Cells were treated with varying levels of R1881 (0, 0.05 nM, 0.5 nM,
1 nM) for 2 or 24 hrs. Transcript levels of two AR target genes, TMPRSS2 and SGK, were measured by qPCR and compared to pLKO control and normalized to the
housekeeping gene, PSMB6. Arrows represent statistically significant up or down regulation of mRNA levels.
doi:10.1371/journal.pone.0038950.t001
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ylation site found in mitogen-activating protein kinases whose
activity is regulated by cell cycle-related kinase (CCRK) and
human protein phosphatase 5 (PP5) [39]. ICK is related to male
germ cell-associated protein kinase (MAK). MAK is an AR co-
regulator that directly binds the AR in co-immunoprecipitation
experiments and enhances AR-dependent transcription in a kinase-
dependent manner [40]. Inhibition of MAK with either RNAi or
a kinase-dead form decreased LNCaP cell growth. The effect of
MAK knockdown on growth parallels our observations with ICK
although we have not observed an effect of ICK on AR
transcription suggesting an alternate mechanism of growth
regulation. ICK can phosphorylate Scythe, an antiapoptotic
protein and thus may regulate cell survival [39,41].
CIT is a dual specificity protein kinase that is a putative RHO
and RAC effector, which may play a role in cytokinesis [42]. CIT
knockdown may disrupt cytokinesis and therefore cell growth.
GALK2 is an N-acetylgalactosamine (GalNAc) kinase, which also
has galactokinase activity at high galactose concentrations [43].
Regulating carbohydrate metabolism is necessary for cell growth
and GalNAc is critical for O-linked glycosylation and the
corresponding regulation of cell signaling [44]; GALK2 knock-
down may disrupt these fundamental cellular processes. PSKH1 is
an understudied kinase that may be a splicing factor compartment-
associated serine kinase with a role in intranuclear non-snRNP
splicing factor trafficking and pre-mRNA processing [45]. The
absence of a major effect in the non-tumorigenic LHS prostate
cells and MCF10A breast cells may be due to differences in the
relative effectiveness of the knockdown and/or requirement for
Figure 4. Kinase knockdown has minimal effect on non-cancer cells. The relative effect of two independent shRNAs per kinase on cell
growth in LHS (A) and MCF10A (B) cells. CyQuant Assay measured DNA content as a surrogate for cell number 7 days after shRNA transduction. n=2
for LHS cells and n=3 for MCF10A cells. Cell growth was compared to pLKO control and the values were averaged across biological replicates. Error
bars represent standard error of the mean.
doi:10.1371/journal.pone.0038950.g004
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that the requirement for CIT, GALK2, and PSKH1 varies
depending upon the tumorigenic state since the mRNA levels of
these kinases increase as prostate cancer progresses (Figure S1).
Further study is required to determine the mechanism of growth
regulation for these kinases in prostate cancer.
In this study we screened a panel of shRNAs targeting the
human kinome against LNCaP prostate cancer cells grown in the
presence and absence of androgen to identify the signaling
pathways that regulate prostate cancer cell growth. We identified
multiple shRNA clones against kinases that regulate both
androgen-dependent and castration-resistant prostate cancer cell
growth. This study further demonstrates the applicability of
lentiviral based shRNA for conducting phenotypic screens to
identify targets involved in a variety of biological processes, and
establishes MAP3K11, DGKD, ICK, CIT, GALK2, and PSKH1
as regulators of prostate cancer cell growth.
Materials and Methods
Cell Culture
LNCaP and C4-2B cells (a gift from Dr. L. W. K. Chung) were
grown in T-Medium (Invitrogen) with 5% Non-Heat Inactivated
(NHI) serum (Gemini) as previously described [32,46,47]. For
growth and RNA experiments, phenol free RPMI media
(Invitrogen) with 5% Charcoal Stripped Serum (CSS) (Gemini)
was used. Cells were stored in incubators at 37uC. LHS (a gift from
Dr. William Hahn) and MCF10A (a gift from Dr. Sarah Parsons)
cells were grown as previously described [25,26,32].
RNAi Screen
MISSIONHLentiExpress Human Kinase Panels, one panel in
the presence of R1881 and one in the absence of R1881, were
used in triplicate per condition. Controls included, in four wells
per plate, lentivirus with shRNA against the androgen receptor
(AR) (NM_000044). AR knockdown was stable under the
Figure 5. AR transcriptional activity in response to MAP3K11 knockdown. (A) Transcript levels of androgen-induced AR target genes that
changed in response to MAP3K11 knockdown in LNCaP cells transduced with two independent shRNAs and pLKO control. RNA was isolated 24 hours
after addition of R1881 at 1 nM. Transcript levels were measured by qPCR, compared to pLKO and normalized to the housekeeping gene, GUS. (B)
Transcript levels of androgen-repressed AR target genes and (C) transcript levels of AR-regulated M-phase genes described in [27]. (B) and (C) were
processed as described for (A). Values were averaged across biological replicates, n=3. Error bars represent standard error of the mean. denotes
statistical significance.
doi:10.1371/journal.pone.0038950.g005
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Additional controls also included, in four wells per plate, the
MISSIONH pLKO.1-puro Control Transduction Particles and
MISSIONH Non-Target shRNA Control Transduction Particles.
The LNCaP human prostate cancer cell line was reverse-
transduced at 6,000 cells per well at multiplicities of infection
(MOI) of approximately 1 in the presence of 8 mg/mL
polybrene (hexadimethrine bromide), then incubated with virus
for approximately 18 hours in a 37uC, 5% CO2 incubator.
Medium was changed and contained either complete medium
with 50 pM R1881 or complete medium prepared with
charcoal-stripped FBS (csFBS). Forty-eight hours post-trans-
duction, all panel plates were placed under 2 mg/mL puromycin
selection, and at 96 hours post-transduction, medium was
changed to fresh complete containing puromycin. On day seven
post-transduction, medium was changed with resazurin solution
added at 10% of the medium volume to all plates. Plates were
incubated as described for three hours and fluorescence was
read at an excitation of 560 nm and an emission of 590 nm.
Data were analyzed by subtracting out background of complete
medium plus resazurin, combining three biological replicates,
and converting all transduced wells in both presence and
absence of R1881 to a growth percentage as compared to
MISSIONH pLKO.1-puro Control wells, which were set at
100%.
Growth Assays
10 MOI of shRNA virus or empty vector pLKO control virus
was added to a 96 well plate previously coated with 1 mg/ml
fibronectin. Puromycin +/2 controls were also plated and did not
Figure 6. MAP3K11 regulates AR S650 phosphorylation. LNCaP and C4-2B cells were transduced with two independent shRNAs targeting
MAP3K11 or pLKO control. Cells were treated with either vehicle or PMA. Total AR was immunoprecipitated and blotted for phospho-S650 and total
AR levels. Cell lysate was blotted for total MAP3K11, total JNK, phospho-JNK, and tubulin. Plotted is the phospho-S650 signal normalized to total AR,
n=3. Quantitation was performed on Odyssey LICOR imaging system. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0038950.g006
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CSS with and without hormone (0.05 nM R1881 or ethanol).
Cells were grown for 7 days under these conditions. On day 2,
puromycin selection was added at a final concentration of 2 mg/ml
to all wells except the puromycin (-) control. On day 4, media was
changed on the plate, with selection and treatment as required.
On day 7, CyQuant Assay (Invitrogen) was performed to
determine cell number. A standard curve was plated with the
appropriate cell line in T-Medium with 5% NHI serum with cell
number varying from 25600 to 0. These cells were allowed to settle
for 3–4 hours and after, all media was removed from the plate and
replaced with 50 ml NF dye diluted 1:500 in 1X HBSS. The cells
then incubated in the dark for 60 minutes at 37uC. Quantification
was performed on a BioTek Synergy 2 plate reader.
Immunoprecipitations and Western Blots
Immunoprecipitations, western blots, and quantitation were
performed as previously described [32,48].
Statistics
For each cell line, two-way ANOVA was used to test for the
effects of the knockdown and level of hormone. F-tests for the
interaction were used to test whether the effect of the knockdown
differed by hormone dose. When the interaction was not
statistically significant, the effect of the knockdown was estimated
by the main effect, averaging over levels of hormone. Growth
measurements were transformed to the log scale to facilitate
interpretation in terms of fold changes relative to control.
RNA Isolation and qPCR
10MOIofshRNAvirusoremptyvectorpLKOcontrolviruswas
addedtoa12wellplatepreviouslycoatedwith1 mg/mlfibronectin.
Puromycin+/2controlswerealsoplatedanddidnotcontainvirus.
80,000 cells per well were plated in RPMI with 5% CSS. On day 2,
puromycin selection was added at a final concentration of 2 mg/ml
in all wells except the puromycin (-) control. On day 3, R1881 was
added at final concentrations of 0.05 nM, 0.5 nM, 1 nM and
ethanolvehiclealone.2hoursand24hoursafterhormoneaddition,
RNAwasisolatedusingRNeasyKit(QIAGEN,Chatsworth,CA)or
preserved using RNALater (Ambion). RNA concentrations were
determined using Ribogreen Assay (Molecular Probes, Inc.,
Eugene,OR).RNAwasreversetranscribedusingtheiScriptcDNA
synthesis kit (Bio-Rad). Quantitative Real-Time PCR (qPCR) was
done using a CFX96 (Bio-Rad). Target kinase mRNA was assessed
using a TaqMan Probe (Applied Biosystems) and an IQ Supermix
with FAM (Bio-Rad) and a 2-step PCR protocol with an extension
and annealing temperature of 60uC. AR target genes and the
housekeeping gene used IQ SYBR Green PCR master mix (Bio-
Rad) or a master mix made with Taq polymerase (Roche), SYBR
Green (Invitrogen). AQP3, FKBP51, GUS, Nkx3.1, PSA, PSMB6,
SGK, STEAP4, and TMPRSS2 were run as described previously
[32,48]. CDC20, CDK1, and UBE2C primers and conditions were
from [27]. DKK, FST, ORM1, and UGT2B were run on a 3-step
protocolwithanannealingandextensiontemperatureof60uC(DKK
forward: 59–CCTTGGATGGGTATTCCAGA–39; DKK reverse:
59–CAGTCTGATGACCGGAGACA–3; FST forward: 59–
TGTGCCCTGACAGTAAGTCG–39; FST reverse: 59–
CCGAAATGGAGTTGCAAGAT–3; ORM1 forward: 59–
GGGTCATTTCCACCACCTCAAACA–39; ORM1 reverse: 59–
GGAGAAAGGCCTTACAGTAGTCTC–3; UGT2B forward:
59– ATGGGAATAAACCAGATGCC–39; UGT2B reverse: 59–
GATCCCATGGTAGATTGCCT–3).
Supporting Information
Figure S1 Oncomine analysis. We examined gene array data
from Oncomine for changes in kinase expression over prostate
cancer disease progression. Shown are box plots from two
independent gene array studies for six kinases that increase in
expression in either primary prostate cancer as compared to
normal prostate or increased in metastatic prostate cancer when
compared to primary disease. In each plot, 1 is the more benign
and 2 is the more advanced stage of disease.
(TIF)
Figure S2 Kinase target knockdown across hormone
dose. Targeted shRNAs knockdown kinase transcript levels in
LNCaP (A) and C4-2B (B) cells. qPCR measured transcript levels
of six kinases after the transduction of two shRNAs per kinase and
pLKO empty vector control. RNA was isolated at 24 hours after
the addition of R1881 at varying concentrations (vehicle, 0.05, 0.5,
and 1 nM). The transcript levels were compared to pLKO (-) and
normalized to the housekeeping gene, PSMB6. Error bars
represent standard error of the mean.
(TIF)
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